Nureca Limited share price

Nureca Limited provides home healthcare and wellness products in India. The company offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeters, glucose meters, and thermometers, as well as connected products; orthopedic products, including massagers, pain management products, posture correctors, and rehabilitation products; and humidifiers and steamers, personal scales, yoga and exercise products, fitness tracking products, and dental and personal care products. It also provides mother and baby care products comprising baby feeding products, carry cots, baby skincare products, and bottle warmers and steamers; nutritional supplements and weight manag…Read more

Website NSE हिंदी में BSE

HealthcareMedical DevicesNSE: NURECAISIN INE0DSF01015

16 Oct 2026, 3:28 PM IST₹320.85▲ 1.15 (0.36%)

Market Cap₹ 321 Cr.
Current Price₹ 320.85
High / Low₹ 376 / 204
Stock P/E74.6
Book Value₹ 189
Dividend Yield0.00 %
ROCE3.0 %
ROE1.10 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 4.30
Price / Book1.69
OPM4.7 %
Debt / Equity0.01
Sales growth (5Y)-7.2 %
Profit growth (5Y)-46.2 %
Promoter holding70.8 %
EV / EBITDA103.9
Beta0.60
All-time high₹ 2,315

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
NURECA	-5.16%	+18.14%	+22.25%	+4.19%	+32.35%	-3.48%	-29.98%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Nureca Limited is in the Medical Devices industry (Healthcare), with a market value of ₹321 crore.
It trades at 74.6 times its last 12 months' earnings and 1.7 times book value.
Revenue grew -7.2% a year over the last 5 years, profit -46.2% a year.
Return on equity was 1.1% and return on capital employed 3.0% in the latest year.
Debt was 0.01 times shareholders' equity.
The share price is 14.7% below its 52-week high and up 32.4% over one year.
Promoters and insiders hold about 70.8%; institutions about 0.0%.

Pros

Company is almost debt-free (debt is 0.01 times equity).
Latest quarter (Jun 2026): sales up 18% and profit up 277% from a year ago.
Promoters have raised their holding by 4.85 points over 3 years, to 68.09%.
Promoters hold a large stake of 68.09%.

Cons

Return on equity has been low: 0.2% on average over the last 3 years.
Sales growth has been slow: -7.2% a year over the last 5 years.
Profit growth has been weak: -46.2% a year over the last 5 years.
Other income makes up 105% of profit before tax.
The company has not paid a dividend recently.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Nureca Limited

Employees: 154
Head office: Chandigarh

HealthcareMedical Devices

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Nureca	320.85	74.6	321	0.00	3	277.37	40	18.04	3.0	1.1	1.69	4.7	0.01	70.84	147	-7.2
2.	Fischer Medical Ventures	29.66	12.7	2,072	0.17	4	-24.30	82	249.42	12.5	8.6	4.98	15.9	0.28	77.25	309	1,097.9
	Median: 2 Co.	175.26	43.6	1,197	0.09	3	126.53	61	133.73	7.8	4.9	3.34	10.3	0.15	74.05	228	545.4

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	21	31	22	17	20	31	26	32	34	72	40	35	40
YOY Sales Growth %	-16.83%	-14.76%	-19.48%	-20.05%	-4.53%	-0.52%	18.28%	87.04%	68.61%	130.58%	49.80%	11.55%	18.04%
	24	30	27	21	23	34	30	31	35	69	36	41	37
Material Cost %	68%	61%	71%	66%	60%	65%	62%	60%	65%	64%	64%	61%	61%
Employee Cost %	13%	10%	15%	18%	18%	12%	15%	13%	13%	12%	11%	12%	11%
Other Expenses %	33%	25%	33%	42%	34%	31%	38%	23%	24%	20%	17%	44%	19%
Operating Profit	-3	1	-4	-4	-2	-2	-4	1	-1	3	3	-6	3
OPM %	-14%	4%	-19%	-26%	-12%	-8%	-15%	4%	-2%	4%	8%	-16%	8%
Other Income	3	3	6	-1	6	3	1	2	3	5	2	1	2
Interest	0	0	0	0	0	0	0	1	0	1	0	0	0
Depreciation	1	1	1	1	1	1	1	1	1	1	1	0	1
Profit before tax	-1	4	1	-6	3	-0	-3	2	1	6	5	-6	4
		26%	83%		37%			-20%	34%	24%	20%		31%
Current tax	0	0	1	0	1	1	-0	-2	0	0	0	2	0
Deferred tax	-0	1	-0	-2	0	-0	-0	2	0	1	1	-1	1
	-1	3	0	-4	2	-0	-3	2	1	4	4	-6	3
YOY Profit Growth %			-45.18%			-116.66%	-1,797.58%		-51.08%			-346.94%	277.37%
EPS in Rs	-0.71	2.90	0.16	-4.15	1.66	-0.48	-2.80	2.47	0.81	4.44	3.91	-6.45	3.21
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	21	31	22	20	23	32	27	32	34	72	40	35	40
YOY Sales Growth %	-18.53%	-14.77%	-19.62%	-7.80%	9.80%	3.24%	21.61%	62.30%	47.24%	122.94%	45.69%	11.51%	17.69%
	24	30	27	24	26	35	32	31	35	71	37	42	38
Material Cost %	70%	64%	76%	78%	72%	71%	71%	65%	71%	70%	71%	67%	67%
Employee Cost %	12%	9%	14%	15%	15%	10%	13%	13%	12%	11%	10%	10%	10%
Other Expenses %	31%	23%	30%	32%	26%	27%	33%	20%	20%	17%	13%	41%	17%
Operating Profit	-3	1	-4	-5	-3	-3	-5	1	-1	2	2	-7	2
OPM %	-14%	3%	-20%	-24%	-13%	-8%	-17%	2%	-3%	2%	6%	-18%	6%
Other Income	3	3	6	-1	6	3	2	2	3	5	2	1	2
Interest	0	0	0	0	0	0	0	1	0	1	0	0	0
Depreciation	1	1	1	1	1	1	0	0	0	1	0	0	1
Profit before tax	-1	4	1	-7	2	-0	-4	1	1	5	4	-6	4
		27%	91%		45%			-38%	34%	25%	20%		33%
Current tax		0	1	-0	1	1	-0	-2	0	0	-0	2	0
Deferred tax	-0	1	-0	-2	0	-0	-0	2	0	1	1	-1	1
	-1	3	0	-4	1	-1	-3	2	1	4	3	-7	2
YOY Profit Growth %			178.57%			-124.51%	-4,316.67%		-53.81%			-419.74%	340.58%
EPS in Rs	-0.74	2.64	0.08	-4.41	1.19	-0.65	-3.29	2.07	0.55	3.69	3.39	-6.95	2.55
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	213	256	111	92	110	147	187
YOY Sales Growth %		19.72%	-56.44%	-17.42%	19.29%	34.02%
	152	200	126	102	117	147	184
Material Cost %	47%	52%	68%	66%	62%	63%	63%
Employee Cost %	2%	4%	14%	13%	14%	12%	11%
Other Expenses %	22%	23%	31%	32%	31%	25%	24%
Operating Profit	62	56	-15	-10	-8	0	4
OPM %	29%	22%	-13%	-11%	-7%	0%	2%
Other Income	3	8	7	11	12	8	10
Interest	2	1	0	0	1	1	1
Depreciation	0	1	2	2	2	2	3
Profit before tax	62	61	-11	-3	1	5	9
	26%	26%			37%	58%	45%
Current tax	16	16	0	2	-1	2
Deferred tax	-1	0	-3	-2	1	1
	46	45	-8	-2	1	2	5
YOY Profit Growth %		-3.05%	-118.35%			146.10%
EPS in Rs	62.04	44.96	-8.25	-1.79	0.85	2.11	5.11

Compounded Sales Growth

5 Years:: -7%
3 Years:: 10%
TTM:: 52%

Compounded Profit Growth

5 Years:: -46%

Stock Price CAGR

5 Years:: -30%
3 Years:: -3%
1 Year:: 32%

Return on Equity

4 Years:: -1%
Last Year:: 1%

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	213	256	112	95	115	147	188
YOY Sales Growth %		19.79%	-56.21%	-15.53%	21.29%	28.41%
	152	200	127	106	124	150	188
Material Cost %	47%	52%	70%	71%	70%	69%	69%
Employee Cost %	2%	4%	14%	12%	13%	10%	10%
Other Expenses %	22%	22%	30%	28%	26%	22%	21%
Operating Profit	62	56	-15	-11	-10	-3	-0
OPM %	29%	22%	-14%	-12%	-8%	-2%	0%
Other Income	3	8	7	11	13	8	10
Interest	2	1	0	0	1	1	1
Depreciation	0	1	2	2	2	2	2
Profit before tax	62	61	-11	-3	-0	3	6
	26%	26%				90%	58%
Current tax	16	16	0	1	-1	2
Deferred tax	-1	0	-3	-2	1	1
	47	45	-8	-2	-1	0	3
YOY Profit Growth %		-2.63%	-118.59%
EPS in Rs	62.25	45.31	-8.42	-2.44	-0.67	0.30	2.68
Dividend Payout %		11%

Compounded Sales Growth

5 Years:: -7%
3 Years:: 10%
TTM:: 49%

Compounded Profit Growth

5 Years:: -64%

Stock Price CAGR

5 Years:: -30%
3 Years:: -3%
1 Year:: 32%

Return on Equity

4 Years:: -1%
Last Year:: 1%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	10	10	10	10
Reserves	185	183	184	171
	3	3	5	2
Long term borrowings		0	1	0
Short term borrowings	0	0	1	0
	8	10	11	13
Trade payables	5	5	7	5
Current liabilities	9	9	12	14
Total Liabilities	207	205	210	196
	6	5	9	12
Gross block	9	7	12	16
Accumulated depreciation	3	2	3	4
Goodwill & intangibles	3	2	2	2
CWIP		0	2	1
	201	200	199	183
Inventories	34	31	40	48
Trade receivables	4	2	3	8
Cash & equivalents	1	14	3	1
Current assets	187	193	190	115
Total Assets	207	205	210	196

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	10	-3	-19	3
Profit for the year	-8	-2	1	2
Working capital changes	29	5	-10	-7
Direct taxes paid	-4	1	-1	0
	-16	18	8	14
Fixed assets purchased	-0	-1	-4	-7
Fixed assets sold			0	0
Investments purchased	-42	-202	-131	-98
Investments sold	25	211	136	112
	-2	-1	-0	-20
Proceeds from borrowings	0	0	2
Repayment of borrowings		-0	-0	-2
Interest paid	-1	-1	-2	-2
Net Cash Flow	-8	14	-11	-2
Free Cash Flow	10	-4	-23	-4

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	-4.2%	-0.9%	0.4%	1.1%
ROCE	—	-5.3%	-1.1%	0.9%	3.0%
Operating margin	—	-15.4%	-13.7%	-9.0%	4.7%
Net margin	—	-7.4%	-2.0%	0.8%	1.4%
Debt / equity	—	0.02	0.01	0.03	0.01
Current ratio	—	21.00	20.77	15.32	8.32
Debtor days	—	14	6	11	19
Inventory days	—	167	184	212	185
Days payable	—	24	31	35	20
Cash conversion cycle	—	157	159	188	184
Working capital days	—	583	728	591	251

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 68.09%
FIIs 0.11%
DIIs 0.24%
Public 31.57%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	63.24%	63.24%	63.24%	63.24%	63.77%	64.06%	64.30%	64.33%	64.97%	64.97%	68.09%	68.09%
	0.10%	0.07%	0.07%	0.07%	0.69%	0.36%	1.07%	0.07%	0.07%	0.08%	0.28%	0.11%
Foreign portfolio investors (Cat. I)					0.62%	0.29%	1.00%			0.01%	0.20%	0.03%
Foreign portfolio investors (Cat. II)	0.10%	0.07%	0.07%	0.07%	0.07%	0.07%	0.07%	0.07%	0.07%	0.07%	0.08%	0.08%
	0.02%	0.02%	0.02%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.24%	0.24%
Alternative investment funds											0.20%	0.20%
	36.65%	36.67%	36.67%	36.65%	35.50%	35.54%	34.59%	35.56%	34.92%	34.91%	31.39%	31.57%
Retail (up to ₹2 lakh)	34.32%	33.61%	33.44%	33.99%	31.61%	32.68%	29.56%	29.08%	30.19%	27.43%	28.10%	28.33%
HNIs (above ₹2 lakh)			0.29%	0.25%	1.36%	0.59%	2.83%	4.03%	1.96%	5.51%	0.73%	0.73%
NRIs	0.75%	0.79%	0.83%	0.74%	0.70%	0.70%	0.55%	0.68%	0.77%	0.81%	0.88%	0.90%
Bodies corporate	0.52%	1.10%	0.98%	0.55%	0.55%	0.53%	0.63%	0.76%	0.92%	0.32%	0.63%	0.59%
No. of Shareholders	52,255	49,600	45,996	43,813	41,986	41,314	39,304	38,075	37,468	35,801	34,558	33,979

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

None filed recently.

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 24 Feb 2022
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Nureca Limited

What is the share price of Nureca Limited today?

Nureca Limited (NURECA) last traded at ₹320.85 on NSE (16 Oct 2026, 3:28 PM IST). Prices may be delayed.

What is the market cap of Nureca Limited?

About ₹321 crore at the latest price.

What is the P/E ratio of Nureca Limited?

About 74.6 times its earnings over the last 12 months.

Is Nureca Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Nureca Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Nureca Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Nureca Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Nureca Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next